Bayer, the German based company logged in at 10th in R&D and 11th in over all sales for 2006. Canadian researchers stopped a study on Trasylol because of the risk of death but Bayer received FDA supplemental New Drug approval for Nexavar (sorafenib). The company announced early in 2007 that it would expand its biotech pipeline and concentrate on new development. The most promising drug in the pipeline is rivaroxaban, a potential blockbuster anti-clotting agent. There are currently 50 drugs in various Phases of clinical trials with another 8 that have been submitted for marketing approval.
Pending approval:
Fosrenol - CKD (Japan)
rThrombin - Bleeding control
Rivaroxaban - VTE prevention
Menostar transdermal - VMS
E2/LNG - HRT (Japan)
Magnevist MRA - MRA
Primovist - MRI
Avelon - PID/New indications (EU)
Phase III:
Rivaroxaban - Medical ill
Rivaroxaban - Stroke prevention in atrial fibriliation
Rivaroxaban - Deep vein thrombosis
VEGF Trap-Eye - Wet AMD
Alemtuzumab - Multiple Sclerosis
Nexavar - Non-small cell lung cancer
Nexavar - Melanoma
Bonefos - Bone Met. prevention in breast cancer
Yaz - Dysmenhorrea
YAZ Flex - Fertility Control
DUB-OC (E2/DNG) - FC - Uterine bleeding
Mirena - Menorrhagia
Angeliz low-low - Menopausal Management
Visanne - Endometrosis
Yasmin plus - Fertility control
LCS (ULD LNG) - Fertility control
Ultravist 370 - CT
Avelox - Unspecified new indications
Zevalin - IND/aggr NHL 1st line
[Source: FierceBiotech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 12, 2007 1:39 PM | Permalink to Trackback